Drug analysis: vericiguat

  • ID: 4462152
  • Drug Pipelines
  • 14 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Vericiguat is a first-in-class soluble guanylate cyclase (sGC) stimulator that acts to increase levels of cyclic guanosine monophosphate (cGMP) via the nitric oxide-sGC-cGMP pathway. In heart failure, there is reduced bioavailability of nitric oxide due to systemic inflammation and vascular dysfunction, resulting in a reduction in cGMP synthesis. Disruption in the nitric oxide-sGC-cGMP pathway results in issues in the regulation of myocardial and renal function, thus resulting in increased potential for myocardial damage.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
vericiguat: Chronic heart failure (CHF)

List of Figures
Figure 1: Vericiguat for chronic heart failure - SWOT analysis
Figure 2: Drug assessment summary of vericiguat for chronic heart failure
Figure 3: Drug assessment summary of vericiguat for chronic heart failure
Figure 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables
Table 1: Vericiguat drug profile
Table 2: Vericiguat Phase III trials in chronic heart failure
Table 3: Vericiguat Phase II data in chronic heart failure
Table 4: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll